Main sector:
Pharma (fully integrated)
Subsectors:
Antibodies
Anti-infectives
Biosimilars
Small molecule therapeutics
Vaccines
Immunotherapy
Indications:
Infectious and parasitic diseases / infectiology / parasitology
Neoplasms / cancer / oncology
Diseases of the blood and blood-forming organs & immune disorders / hematology / immunology
Endocrine, nutritional and metabolic diseases / endocrinology
Mental and behavioural disorders / psychiatry /psychology
Diseases of the nervous system / neurology
Diseases of the eye / ophthalmology
Cardiovascular / cardiology
Respiratory / pulmonology
Digestive system / gastroenterology
Skin and subcutaneous tissue / dermatology
Musculoskeletal system and connective tissue / Orthopedics
Genitourinary system / Urology
Congenital malformations, deformations and chromosomal abnormalities / medical genetics
Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified
Injury, poisoning and certain other consequences of external causes / toxicology
External causes of morbidity and mortality / traumatology
Social circumstances / substance related disorders / addiction
Products
In development: 184
On the market: 14
Description:
AstraZeneca is a global, science-led biopharmaceutical company that focuses on discovering, developing, and commercializing prescription medicines in oncology, rare diseases, and biopharmaceuticals, including cardiovascular, renal & metabolism, and respiratory & Immunology. The company's products includes Imfinzi (durvalumab) is a human monoclonal antibody that binds to the PD-L1 protein and blocks the interaction of PD-L1 with the PD-1 and CD80 proteins, countering the tumor's immune-evading...
